May 4- U.S. mall owner Macerich Co plans to terminate its stockholder rights plan and add two new independent directors as part of a settlement with an activist investor group. Activist investor Jonathan Litt nominated four directors to Macerich's board last month, after the company rejected a takeover bid from larger rival Simon Property Group Inc, a person...» Read More
CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.
Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.
In an SEC Filing, Valeant Pharmaceuticals said it expected to offer a mix of stock and about $15 billion in cash for botox maker Allergan. David Krempa, Morningstar equity analyst, and CNBC's Meg Tirrell, provide perspective.
Activism in the long-term is not only bad for shareholders but also bad for the economy as a whole, says Martin Lipton, Wachtell, Lipton, Rosen & Katz, expressing his views on shareholder activism. Also Lipton shares his thoughts on the two categories of hedge fund activism.
Eileen Nugent, Skadden, Arps, Slate, Meagher & Flom, and Robert Spatt, , Simpson Thacher & Bartlett, discuss go-shop deals in the M&A environment and the latest LBO buzz from New Orleans.
Sam Zell, Equity Group Investments chairman, shares his thoughts on the strength of the U.S. economy. We have to focus on growth, says Zell. James Bullard, Federal Reserve Bank of St. Louis president and CEO, weighs in.
Sam Zell, Equity Group Investments chairman, discusses backing an activist campaign to unseat the board and management of CommonWeath, a real estate investment trust that owns more than 300 office buildings.
CNBC's Scott Wapner reports Dan Loeb's Third Point will nominate three members to Sotheby's board of directors including Loeb himself.
Australian Treasurer Joe Hockey will allow Archer Daniel Midland to lift its stake in Graincorp to 24.9 percent. CNBC's Matthew Taylor reports.
Activist investor Carl Icahn reported a 12.63 stake in medical device maker Hologic, prompting the company to seek protection from a hostile takeover
With a takeover of Blackberry looming, CNBC's Jim Cramer says the security and intellectual property of Blackberry is invaluable.
CNBC's Kayla Tausche reports Twitter is staggering its board so it is less susceptible to a takeover.
BlackBerry has underperformed recently, while Microsoft is on a tear. Peter Misek of Jefferies, weighs in on whether Microsoft should buy BlackBerry.
CNBC's David Faber reports the latest details on Michael Dell and Silver Lake's attempts to take the PC maker private, and provides an update on Community Health's attempts to acquire Health Management Associates for $3.9 billion.
Despite the postponement of the shareholder vote, David Eaton, Vice President of Proxy Research at Glass Lewis, says 11th-hour backing from some large investors shows there is more support for Michael Dell's buyout plan than initially thought.
One person with a lot at stake in the Dell shareholder decision is Carl Icahn, reports CNBC's Scott Wapner.
Dell shareholder Norm Peters provides perspective on the adjournment of Dell's shareholder meeting and the future of the PC maker.
According to Reuters it appears Michael Dell does not have enough shareholder votes to take his company private, reports CNBC's Andrew Ross Sorkin.
CNBC's Jackie DeAngelis provides a preview of what to expect from today's possible shareholder vote on Michael Dell and Silver Lake's proposed acquisition of the PC maker. And Scott Wapner has an update on Carl Icahn's opposition to the deal, with Joe Weisenthal, Business Insider executive editor.
Evan Staples, Nuveen Asset Management, discusses the likelihood of Pepsi making a run for Mondelez.